<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Bosentan</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00559</strong>&#160; (APRD00829)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Bosentan is a dual endothelin receptor antagonist important in the treatment of pulmonary artery hypertension (<span class="caps">PAH</span>). It is licensed in the United States, the European Union and other countries by Actelion Pharmaceuticals for the management of <span class="caps">PAH</span> under the trade name Tracleer&#174;. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00559/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00559/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00559.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00559.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00559.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00559.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00559.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00559">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>Bosentan hydrate</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Tracleer</td><td>Actelion</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antihypertensive-agents">Antihypertensive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>147536-97-8</td></tr><tr><th>Weight</th><td>Average: 551.614<br>Monoisotopic: 551.183854375</td></tr><tr><th>Chemical Formula</th><td>C<sub>27</sub>H<sub>29</sub>N<sub>5</sub>O<sub>6</sub>S</td></tr><tr><th>InChI Key</th><td>GJPICJJJRGTNOD-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C27H29N5O6S/c1-27(2,3)18-10-12-19(13-11-18)39(34,35)32-23-22(38-21-9-6-5-8-20(21)36-4)26(37-17-16-33)31-25(30-23)24-28-14-7-15-29-24/h5-15,33H,16-17H2,1-4H3,(H,30,31,32)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)pyrimidin-4-yl]benzene-1-sulfonamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Superclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Class</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).</td></tr><tr><th>Pharmacodynamics</th><td>Bosentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Bosentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects.</td></tr><tr><th>Mechanism of action</th><td>Endothelin-1 (ET-1) is a neurohormone, the effects of which are mediated by binding to ET<sub>A</sub> and ET<sub>B</sub> receptors in the endothelium and vascular smooth muscle. ET-1 concentrations are elevated in plasma and lung tissue of patients with pulmonary arterial hypertension, suggesting a pathogenic role for ET-1 in this disease. Bosentan is a specific and competitive antagonist at endothelin receptor types ET<sub>A</sub> and ET<sub>B</sub>. Bosentan has a slightly higher affinity for ET<sub>A</sub> receptors than for ET<sub>B</sub> receptors.</td></tr><tr><th>Absorption</th><td>Absolute bioavailability is approximately 50% and food does not affect absorption.</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>18 L</li>
</ul></td></tr><tr><th>Protein binding</th><td>Greater than 98% to plasma proteins, mainly albumin.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Bosentan is metabolized in the liver by the cytochrome P450 enzymes CYP2C9 and CYP3A4 (and possibly CYP2C19), producing three metabolites, one of which, Ro 48-5033, is pharmacologically active and may contribute 10 to 20% to the total activity of the parent compound.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Bosentan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00133">Bosentan metabolite Ro 48-5033</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/133">Details</a></td></tr><tr><td>Bosentan</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li>
<li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li></ul></td><td><a href="/metabolites/DBMET00134">Bosentan metabolite Ro 47-8634</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/134">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00133">Bosentan metabolite Ro 48-5033</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01237">Bosentan metabolite Ro 64-1056</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1392">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00134">Bosentan metabolite Ro 47-8634</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01237">Bosentan metabolite Ro 64-1056</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1393">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Bosentan is eliminated by biliary excretion following metabolism in the liver.</td></tr><tr><th>Half life</th><td>Terminal elimination half-life is about 5 hours in healthy adult subjects.</td></tr><tr><th>Clearance</th><td><ul>
	<li>4 L/h [patients with pulmonary arterial hypertension]</li>
</ul></td></tr><tr><th>Toxicity</th><td>Bosentan has been given as a single dose of up to 2400 mg in normal volunteers, or up to 2000 mg/day for 2 months in patients, without any major clinical consequences. The most common side effect was headache of mild to moderate intensity. In the cyclosporine A interaction study, in which doses of 500 and 1000 mg b.i.d. of bosentan were given concomitantly with cyclosporine A, trough plasma concentrations of bosentan increased 30-fold, resulting in severe headache, nausea, and vomiting, but no serious adverse events. Mild decreases in blood pressure and increases in heart rate were observed. There is no specific experience of overdosage with bosentan beyond the doses described above. Massive overdosage may result in pronounced hypotension requiring active cardiovascular support.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9253</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.7419</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.8956</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Non-substrate
        </td>
        <td>0.5738</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.6175</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5092</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9149</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.5926</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9117</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5132</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7203</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.518</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8755</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.5219</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.8407</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.772</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6147
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.6515
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.2676 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9679
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.572
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Actelion ltd</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.actelion.com">Actelion Pharmaceuticals Inc.</a></li>
<li>Action Pharmaceuticals Ltd.</li>
<li><a href="http://haupt-pharma.de">Haupt Pharma</a></li>
<li><a href="http://www.patheon.com">Patheon Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Tablet, film coated</td><td>Oral</td><td>125 mg</td></tr><tr><td>Tablet, film coated</td><td>Oral</td><td>62.5 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01418">Acenocoumarol</a></td><td>Bosentan may decrease the anticoagulant effect of acenocoumarol by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB01125">Anisindione</a></td><td>Bosentan may decrease the anticoagulant effect of anisindione by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB01076">Atorvastatin</a></td><td>Bosentan may decrease the serum concentration of atorvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of atorvastatin if bosentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00439">Cerivastatin</a></td><td>Bosentan may decrease the serum concentration of cerivastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of cerivastatin if bosentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00091">Cyclosporine</a></td><td>Cyclosporine may increase the effect and toxicity of bosentan.</td></tr><tr><td><a href="/drugs/DB00266">Dicoumarol</a></td><td>Bosentan may decrease the anticoagulant effect of dicumarol by increasing its metabolism.</td></tr><tr><td><a href="/drugs/DB08866">Estradiol valerate/Dienogest</a></td><td>Affects CYP3A4 metabolism, decreases or effects levels of Estradiol valerate/Dienogest.  </td></tr><tr><td><a href="/drugs/DB00977">Ethinyl Estradiol</a></td><td>Bosentan may decrease the contraceptive effect of ethinyl estradiol. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.</td></tr><tr><td><a href="/drugs/DB01016">Glyburide</a></td><td>Increased risk of hepatic toxicity</td></tr><tr><td><a href="/drugs/DB01167">Itraconazole</a></td><td>Itraconazole may increase the effect and toxicity of bosentan.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole may increase the effect and toxicity of bosentan.</td></tr><tr><td><a href="/drugs/DB00227">Lovastatin</a></td><td>Bosentan may decrease the serum concentration of lovastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of lovastatin if bosentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08815">Lurasidone</a></td><td>Concomitant therapy with a CYP3A4 substrate and inducer will decrease levels of lurasidone. Coadministration with lurasidone is contraindicated. </td></tr><tr><td><a href="/drugs/DB00603">Medroxyprogesterone Acetate</a></td><td>Bosentan may decrease the contraceptive effect of medroxyprogesterone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.</td></tr><tr><td><a href="/drugs/DB01357">Mestranol</a></td><td>Decreases the effect of contraceptive</td></tr><tr><td><a href="/drugs/DB00717">Norethindrone</a></td><td>Bosentan may decrease the contraceptive effect of norethindrone. Hormonal contraception should not be relied on alone during concomitant therapy with bosentan.</td></tr><tr><td><a href="/drugs/DB01656">Roflumilast</a></td><td>Affects CYP3A4 metabolism, decreases level or effect of roflumilast. </td></tr><tr><td><a href="/drugs/DB00641">Simvastatin</a></td><td>Bosentan may decrease the serum concentration of simvastatin by increasing its metabolism. Monitor for changes in the therapeutic and adverse effects of simvastatin if bosentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Co-administration may cause decreased Telithromycin and increased Bosentan plasma concentrations. Consider alternate therapy.</td></tr><tr><td><a href="/drugs/DB06287">Temsirolimus</a></td><td>Bosentan may increase the metabolism of Temsirolimus decreasing its efficacy. Concomitant therapy should be avoided.  	</td></tr><tr><td><a href="/drugs/DB01124">Tolbutamide</a></td><td>Tolbutamide, a strong CYP2C9 inhibitor, may decrease the metabolism and clearance of Bosentan. Consider alternate therapy or monitor for changes in Bosentan therapeutic and adverse effects if Tolbutamide is initiated, discontinued or dose changed. </td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Bosentan may decrease the effect of Tramadol by increasing Tramadol metabolism and clearance. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>The CYP3A4 inducer, Bosentan, may decrease Trazodone efficacy by increasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Bosentan is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB08867">Ulipristal</a></td><td>Concomitant therapy with strong CYP3A4 inducers may decrease plasma concentrations of ulipristal and ultimately its effectiveness. Avoid combination therapy. </td></tr><tr><td><a href="/drugs/DB05294">Vandetanib</a></td><td>Decreases levels of vandetanib by affecting CYP3A4 metabolism. Contraindicated. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of bosentan by decreasing its metabolism. Monitor for changes in the therapeutic and adverse effects of bosentan if voriconazole is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00682">Warfarin</a></td><td>Bosentan may decrease the anticoagulant effect of warfarin by increasing its metabolism.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Take without regard to meals.</li></ul></td></tr></tbody></table>